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Introduction
Type 1 diabetes mellitus (T1DM) is a chronic lifelong disease, 
commonly diagnosed in youth, that requires strict multidis-
ciplinary treatment for the patient’s entire life.1 Over the last 
decades, the incidence of T1DM has been increasing in most 
regions of the world.2,3 In the State of São Paulo in Brazil, 
the average annual incidence of T1DM between 1987 and 
1991was 7.6 per 100 000.4 Additionally, in the city of Bauru 
in the same state, the incidence of T1DM in children younger 
than 15 years, increased 9.6 times from 1986–2006, especially 
among children of low socioeconomic status between the ages 
of 5 and 9 years.5 
T1DM is associated with long-term complications that 
cause high morbidity and mortality,6 affect the quality of life 
and increase health-care costs.7,8 In the Diabetes Control and 
Complications Trial (conducted from 1983 to 1993) and its 
follow-up study, known as the Epidemiology of Diabetes In-
terventions and Complications study (DCCT/EDIC), which 
assesses incidence, predictors of complications, and the impact 
and cost-effectiveness of intensive versus standard control, 
intensive control has been shown to reduce the development 
of microvascular and cardiovascular complications2,9 and to 
be cost-effective.10 Nonetheless, approximately one third of the 
patients who participated in our study were not screened for 
chronic complications over the previous year and the majority 
did not meet metabolic control goals.11
In the United States of America, average health expendi-
ture is 2.3-fold higher for people with diabetes than for people 
without the disease.8 In a study in Scotland, the hospitaliza-
tion rate and inpatient costs among people with diabetes were 
2.1- and 2.2-fold greater, respectively, than among the general 
population.12 Most costing studies on diabetes include both 
T1DM and type 2 diabetes mellitus (T2DM),8 or only T2DM.13 
Hence, little is known about the impact of T1DM alone.12 
Although previous studies have investigated the costs associ-
ated with diabetes in Brazil,7,14 the impact of T1DM alone has 
never been assessed.
The objective of this study was to perform a partial eco-
nomic evaluation of the direct medical costs of T1DM, from 
the public health-care system’s perspective, in a representative 
sample of patients attending the public health-care system in 
Brazil. We also aimed to identify and quantify the contribu-
tion of individual determinants to the total direct costs. Data 
on the use of resources and on the costs of T1DM from the 
public health-care system’s perspective will allow health-care 
providers to better understand the effects of the disease, define 
management strategies and appropriately allocate resources.
Methods
Study design
This study was a retrospective, cross-sectional cost-of-illness 
study conducted nationwide at multiple centres between 
December 2008 and December 2010. The centres were 28 
Brazilian secondary and tertiary public care clinics located 
in urban centres in four geographic regions of Brazil: north/
north-east, mid-west, south-east and south. All patients re-
ceived health care from the National Brazilian Health Care 
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System (NBHCS). We determined the 
number of patients enrolled in the 
study in each region on the basis of the 
estimated prevalence of T1DM in Bra-
zil and the population density in each 
geographic region. Since patients with 
T1DM in Brazil are usually treated at 
secondary or tertiary centres, primary 
care centres were not included in the 
study. Each clinic provided data from at 
least 50 consecutive outpatients with an 
initial diagnosis of T1DM who regularly 
attended the clinic. Data were collected 
through interviews during clinic visits 
using a chart form. The detailed meth-
ods have been described elsewhere.11 
Written informed consent for the study 
was obtained from all patients aged 18 
years or older or from the parents or 
guardians of patients younger than 18 
years. The study was approved by each 
local centre’s ethics committee. Only 
patients who had had at least 12 months 
of follow-up at the centre were included 
in the cost-of-illness study. This inclu-
sion criterion allowed us to quantify the 
variables required to determine costs 
over the year that preceded the study.
Clinical and demographic 
variables
We obtained demographic data and 
data on economic status and defined 
economic status according to the Brazil-
ian Economic Classification Criteria,15 
used to estimate the purchasing power 
of urban individuals and families and 
to classify the urban population into 
economic strata. These criteria provide 
scores based on the ownership of items 
and educational level.15 We defined the 
duration of the diabetes as the time 
elapsed since the diagnosis.
During the clinic interviews we 
obtained information on diabetic 
treatment modalities; source of insu-
lin pumps, medications and supplies 
for self-monitoring of blood glucose 
(SMBG); frequency of SMBG, and 
routine diabetes care. We obtained 
the following information from medi-
cal records: total number of glycated 
haemoglobin (HbA1c) measurements 
over the prior year, fructosamine levels, 
fasting and 2-hour postprandial gly-
caemia, total cholesterol, low-density 
lipoprotein (LDL), high-density lipo-
protein (HDL), triglycerides, uric acid, 
plasma creatinine, plasma urea, sodium, 
potassium, liver enzymes (aspartate 
[AST] and alanine aminotransferase 
[ALT]), C-reactive protein (CRP), 
thyroid-stimulating hormone (TSH), 
urine protein and urine albumin. We 
recorded the number of tests performed 
to screen for complications of diabetes, 
such as electrocardiograms, exercise 
stress tests, stress echocardiographs, 
calcium score tomographies, coronary 
artery angiographs and fundoscopies. 
We also analysed the frequency of vari-
ous medical procedures, such as vitrec-
tomy, laser therapy and haemodialysis, 
and of hospitalizations due to diabetes 
decompensation or ketoacidosis.
Costs and health-care resource 
distribution
We calculated direct medical costs from 
the costs of medications (oral drugs 
and insulin), SMBG supplies, blood 
analysis and other tests, consultations 
with physicians, nurses and dietitians, 
medical procedures and hospitaliza-
tions during the preceding year. The 
drugs included in the analysis were 
those used specifically to treat T1DM 
or its comorbidities (arterial hyperten-
sion, dyslipidaemia, obesity) and related 
complications (diabetic nephropathy/
chronic renal failure, neuropathy and 
neuropathic pain, retinopathy, cardio-
vascular disease). We also included the 
costs of the nutritional supplements 
given to patients with chronic renal 
failure or neuropathy, such as calcium, 
vitamin D and vitamin B12. In the case 
of drugs provided by public institutions, 
we obtained the costs from the web site 
of the Brazilian Ministry of Health16; 
for drugs that were privately acquired, 
we used the average price found in 
three nationwide pharmaceutical web 
sites. These privately-acquired drugs 
include medications or supplies that are 
not standardized by the health system. 
When the price varied by region, we 
calculated an average cost. We obtained 
the costs of tests and medical procedures 
from a 2010–2011 NBHCS source that 
gives the prices used to reimburse public 
health-care units. The cost of insulin 
pumps and administration supplies was 
based on what the Municipal Health 
Bureau of Rio de Janeiro (RJ-SMS) paid 
in May 2010 (Roche®). We determined 
the costs of SMBG supplies from what 
the RJ-SMS paid in April 2011 or, when 
privately acquired, by calculating the 
mean costs for three nationwide phar-
maceutical companies.
We converted all costs to United 
States dollars (US$) using a conversion 
rate of US$ 1.00 = 1.9315 reais, which 
was the average for the period from 
2008 to 2010.
Data storage and statistical 
analysis
We used Excel 2010 for Windows 
to store the data and we performed 
the statistical analysis with SPSS ver-
sion 17.0 (SPSS Inc., Chicago, United 
States of America). The data are pre-
sented in Table 1 as count (percentage), 
mean ± standard deviation (SD) and me-
dian followed by its interquartile range. 
The costs are presented as means with 
their 95% confidence intervals (CIs). 
We log-transformed the non-normally 
distributed variables and compared 
means using t-tests or ANOVA.
Results
Of the 3591 patients initially evaluated, 
3180 were included in this study. The 
study population consisted of 56.3% 
females and 57.4% Caucasians. The av-
erage age was 22 years  (SD: ± 11.8) and 
average disease duration was 10.3 years 
(SD: ± 8.0). Table 1 shows the demo-
graphic and economic data pertaining 
to the study population.
The overall direct medical cost per 
capita was US$ 1319.15. The expenditure 
related to treatment – US$ 1216.33 per 
patient per year – represented 92.20% of 
this total direct medical cost. Insulin ad-
ministration supplies and SMBG – US$ 
696.78 per patient per year – accounted 
for 52.82% of total direct medical costs. 
The expenditure on insulin pump and 
its supplies represented 5.5% of the to-
tal direct cost. Only 38 (1.2%) patients 
used this treatment modality, at an 
average cost per patient of US$ 6069.26. 
Medical procedures and haemodialysis 
accounted for 5.73% – US$ 75.64 per 
patient per year – of the direct medical 
costs. The cost of consultations – US$ 
25.62 per patient per year – accounted 
for 1.94% of direct medical costs. The 
data are presented in Table 2.
The direct medical costs associated 
with T1DM, stratified by patients’ de-
mographic characteristics, are presented 
in Table 3. We found no significant dif-
ferences in costs by sex and age range. 
However, the longer the duration of the 
diabetes and the higher the socioeco-
nomic status, the higher the costs. Costs 
showed a significant 1.56-fold increase 
between diabetes of less than 5 years’ 
duration and diabetes whose duration 
was 15 years or longer. Similarly, costs 
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were a significant 1.65 times higher 
among patients in the high socioeco-
nomic stratum than among patients in 
the socioeconomic stratum classified 
as very low.
Discussion
This study is the first to estimate the di-
rect medical costs of T1DM in a Brazil-
ian sample of patients. T1DM represents 
an average cost of US$ 1319.15 per pa-
tient for the NBHCS. Importantly, most 
expenditures were related to therapy, 
largely insulin, and to SMBG supplies, 
which are items that all patients with 
T1DM require. These requirements 
may explain why the per capita medical 
costs calculated in this study are higher 
than the costs found in studies that have 
mostly7 or exclusively included T2DM 
patients,13 who use insulin far less often 
than patients with T1DM. In 2007 in the 
United States, young insulin-treated pa-
tients in the private health-care system 
faced costs that were 1.64 times higher 
than those faced by patients who were 
not treated with insulin. The expendi-
ture on diabetes supplies was 10 times 
higher among insulin-treated patients 
than among patients not treated with 
insulin. Regardless of the treatment 
modality, outpatient expenditures con-
stituted the largest total expenditure (43 
and 58% for insulin-treated and non-
insulin-treated youths with diabetes, 
respectively), followed by prescription 
drugs other than insulin (39 and 26%, 
respectively) and inpatient expenditures 
(18 and 17%, respectively).17 These find-
ings are consistent with ours because 
medications and blood glucose monitor-
ing accounted for the largest fraction of 
the direct costs in our study.
As shown, treatment technologies 
accounted for most public expendi-
ture; human resources accounted for 
little expenditure. These differences in 
the apportionment of Brazilian public 
health resources must be carefully 
examined because more money is be-
ing spent on SMBG supplies than on 
physician and dietitian consultations 
and nurse counselling. These findings 
point to the need to pay greater, more 
logistical and financial attention to the 
integral health assistance model, which 
involves investing in a multidisciplinary 
team and focusing on health education 
and on the rational and effective use of 
the procedures and technologies avail-
able. The complex treatment of T1DM, 
which requires vigilance and frequent 
monitoring, underscores the importance 
of the physician–patient relationship in 
establishing a partnership conducive 
to better treatment adherence. In fact, 
despite the high cost of SMBG, most 
patients in our sample had inadequate 
metabolic control, as found in previous 
studies.11,18 Factors other than effective 
SMBG are known to influence metabolic 
control, but it is clear that access to a 
given technology does not guarantee its 
correct use by the patient or good adher-
ence to recommendations. Continued 
education is helpful but depends on the 
availability of capable staff trained for 
this purpose.
In a study of the costs associated 
with diabetes in Latin America, ap-
proximately US$ 607 were spent per 
patient annually, on average, in Chile 
and Mexico, whose gross national prod-
ucts are roughly equal to that of Brazil.7 
In this study, however, cost estimates 
were based on a standard generalized 
protocol that included three visits to 
a general practitioner, one visit to an 
ophthalmologist, one HbA1c test, one 
lipid profile, one electrocardiogram, 
one urine test (for proteinuria), and 
treatment with insulin or oral drugs. 
Thus, the results do not reflect actual 
individualized clinical expenditures, and 
costs may have been underestimated. In 
Brazil, the direct costs per capita and the 
overall health expenditure associated 
Table 1. Clinical and demographic characteristics of patients with type 1 diabetes 
mellitus (n = 3180), Brazil, 2008–2010
Characteristic Value
Female sex, no. (%) 1791 (56.3)
Mean age, years (SD) 22 (11.8) 













Very low 1102 (34.7)
Occupation, no. (%)
Current worker 997 (31.4)
Unemployed 232 (7.3)
Temporarily medically disabled by NISS 52 (1.6)
Retired because of diabetes 85 (2.7)
Student 1483 (46.6)
Otherc 331 (10.4)
Level of care, no. (%)
Secondary 897 (28.2)
Tertiary 2283 (71.8)
Mean diabetes duration,d years (SD) 10.3 (8.04)
HbA1c, % (SD) 9.34 (2.34)
With microvascular complications,e no. (%) 635 (27.4)
With macrovascular complications,e no. (%) 119 (5.1)
HbA1c, glycated haemoglobin; NISS, National Institute of Social Security; SD, standard deviation.
a  Afro-Brazilians, Mulattos, Asians, native Indians.
b  Data missing for 87 participants.
c  Includes preschool children, homemakers, volunteers and those who retired for reasons unrelated to 
diabetes.
d  Defined as the time elapsed since diagnosis.
e  Excludes patients without criteria for the screening for diabetic complications (n = 863).
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with diabetes per capita were US$ 872 
and US$ 270, respectively.7
In Brazil, the costs of certain drugs 
for diabetes and hypertension are fully 
subsidized by the public sector; the fed-
eral government co-subsidizes private 
sector expenses through the Programa 
Farmácia Popular do Brasil (Brazilian 
Popular Pharmacy Programme), devel-
oped by the health ministry. The public 
system also provides SMBG supplies, 
but not always in the amount needed or 
recommended for optimal patient moni-
toring and seldom uniformly across cit-
ies. Moreover, because the medications 
available through this programme do 
not always meet the patient’s needs, 
some treatment costs must be paid by 
the patient or his family. Therefore, 
diabetes drugs and supplies can take 
up a substantial fraction of a family’s 
income. Given that in 2009 the average 
Brazilian household had 3.1 members 
(4.2 if in the poorest socioeconomic 
category), any increase in household 
expenditures could undermine a fam-
ily’s quality of life.19 Approximately 68% 
of the participants in our study were 
of low or very low economic status. To 
save money, these individuals may use 
their supplies inappropriately (e.g. they 
may reuse disposable supplies, use lower 
doses of medication or perform SMBG 
less often than recommended by clini-
cal diabetes monitoring and treatment 
guidelines). As our results showed, the 
costs associated with diabetes are greater 
among patients of higher economic 
status. For patients of very low and low 
economic status, costs are 65% and 39% 
lower than for patients of high economic 
status. This may be because people of a 
higher educational level may seek and 
adhere to more complex and expensive 
therapeutic regimens.
A study conducted in Israel in the 
1990s projected the estimated costs of 
T1DM over a 35-year period.20 The re-
sults indicated that early in the disease, 
basic treatment accounts for approxi-
mately 70% of total expenditures. How-
ever, in the later stages the costs associ-
ated with the complications of diabetes 
increase substantially.20 In the present 
study, the per capita costs rose with the 
duration of the diabetes. Patients who 
had had diabetes longer than 15 years 
had costs about 56% higher than those 
who had had the disease for less than 
5 years. It is reasonable to assume that 
disease-related expenditures will rise in 
future years since costs increase in pro-
portion to the duration of the diabetes 
and the incidence of T1DM is increasing 
among younger age groups.3 To date, no 
national multicentre epidemiological 
studies on the prevalence or incidence 
of T1DM have been conducted and the 
actual and future impact of the disease 
Table 2. Average annual direct medical costs of inpatient and outpatient treatment of 






annual cost  
per capita (US$)
Consultations 81 473.67 1.94 25.62
Tests 161 817.64 3.86 50.89
Outpatient treatment 3 867 915.66 92.20 1216.33
Insulin 1 093 215.69 26.06 343.78
Oral drugs 87 782.17 2.09 27.60
Supplies for self–monitoring of blood 
glucose 
2 215 749.68 52.82 696.78
Insulin pump and supplies 230 631.80 5.50 72.53
Medical procedures/haemodialysis 240 536.32 5.73 75.64
Hospitalizations 83 685.41 2.00 26.32
Total direct medical costs 4 194 892.39 100.00 1319.15
US$, United States dollar. 
Table 3. Direct medical costs associated with type 1 diabetes mellitus, by patients’ 
demographic characteristics, Brazil, 2008–2010




Male 1288.23 (1 214.20–1362.25)
Female 1343.13 (1 273.41–1412.85)
Ethnicity 0.013
Caucasian 1374.85 (1 309.26–1440.43)




10–14 1198.92 (1 127.20–1270.64)
15–29 1306.83 (1 233.62–1380.03)
≥ 30 1564.72 (1 420.11–1709.34)
Diabetes durationb (years) 0.000c
< 5 1086.89 (1 023.51–1150.28)
≥ 5 but < 10 1220.69 (1 146.55–1294.82)
≥ 10 but < 15 1301.80 (1 194.11–1409.50)
≥ 15 1696.60 (1 549.52–1843.68)
Socioeconomic status 0.000d
High 1806.44 (1 565.34–2047.55)
Medium 1561.45 (1 437.53–1685.37)
Low 1302.24 (1 219.04–1385.45)
Very low 1098.12 (1 022.02–1174.23)
CI, confidence interval; US$, United States dollar.
a  Afro-Brazilians, Mulattos, Asians, native Indians.
b  Defined as the time elapsed since diagnosis. 
c  P-value is for the following age comparisons: ≥ 15 years versus < 5 years; ≥ 15 years versus ≥ 5 but < 10 
years; ≥ 15 years versus ≥ 10 but < 15 years. Other comparisons were not statistically significant.
d  P-value is for the following comparisons of socioeconomic status: high versus low; high versus very 
low; medium versus low; medium versus very low. The comparison between high and medium 
socioeconomic status was not statistically significant.
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صخلم
ليزابرلا في ينطولا ديعصلا لىع زكارلما ةددعتم ةسارد :لولأا طمنلا نم يركسلا ءاد ةفلكت
 طمنلا  نم  يركسلا  ءادل  ةشرابلما  ةيبطلا  فيلاكتلا  ديدتح  ضرغلا
 ليزابرلا  في  ةيحصلا  ةياعرلل  ينطولا  ماظنلل  )T1DM(  لولأا
 ةيلاجملإا ةفلكتلا في نوكم لك ماهسإ ةيعون ديدتحو )NBHCS(
.يدرف وحن لىع
 لىع  تاعاطقلا  ةددعتم  ةيعاجترسا  ةسارد  ءارجإ  مت  ةقيرطلا
 ةدايع  28  في  2010  لىإ  2008  نم  ةترفلا  في  ينطولا  ديعصلا
 3180  لىع  ةساردلا  تلمتشاو  .ةيليزارب  ةنيدم  20  في  ةيمومع
 ةنس  22  رمعلا  طسوتم(  لولأا  طمنلا  نم  يركسلا  ءادب  ًاضيرم
 مهيقلت دنع ةيئاصقتسلاا ةسرادلل مهعاضخإ مت ثيح )11.8 ±
 .ليزابرلا  في ةيحصلا  ةياعرلل  ينطولا  ماظنلا  نم ةيحصلا  ةياعرلا
 متو .)8.0 ±( ةنس 10.3 ميهدل يركسلا ءاد ةدم طسوتم ناكو
 تاخضمو ةيبطلا تاءارجلإاو تارابتخلاا فيلاكت لىع لوصلحا
 ربلإاو  نقاحلماو  تادادملإاو  ءاودلا  لوانت  تادادمإو  ينلوسنلأا
 )SMBG(  مدلا  في  زوكولغلا  ىوتسلم  تياذلا  دصرلا  لجأ  نم
 لىإ  2010  نم  ةترفلل  ليحلماو  ينطولا  ةحصلا  ماظن  رداصم  نم
 ةفاضإب ةشرابلما ةيونسلا ةيبطلا فيلاكتلا صلاختسا متو .2011
 ةيبطلا  تاراشتسلااو  تارابتخلااو  تادادملإاو  ةيودلأا  فيلاكت
 ماعلا  رادم  لىع  تايفشتسلما  لىإ  لوخدلا  تارمو  تاءار�جلإاو
.ةلباقملل قباسلا
 1319.15 درفلل ةشرابلما ةيونسلا ةيبطلا ةفلكتلا طسوتم غلب جئاتنلا
 1216.33  –  جلاعلاب  لصتلما  قافنلإا  لثمو  .ًايكيرمأ  ًارلاود
 فيلاكتلا لياجمإ نم % 92.20 – ًايونس ضيرملل ًايكيرمأ ًارلاود
 لىإ فيلاكتلا هذه لياجمإ نم % 52.82 ةبسن ىزعتو .ةشرابلما ةيبطلا
 زوكولغلا ىوتسلم تياذلا دصرلاو ينلوسنلأا لوانت ةرادإ تادادمإ
 ةبسن ىزعتو .)ًايونس ضيرملل ًايكيرمأ ًارلاود 696.78( مدلا في
 ًايكيرمأ  ًارلاود  75.64(  ةشرابلما  ةيبطلا  فيلاكتلا  نم  %  5.73
 ىزعتو  .ًاعم  مدلا  لسغو ةيبطلا  تاءارجلإا  لىإ  )ًايونس ضيرملل
 ًارلاود  25.62(  ةشرابلما  ةيبطلا  فيلاكتلا  نم  %  1.94  ةبسن
.تاراشتسلاا لىإ )ًايونس ضيرملل ًايكيرمأ
 نم يركسلا ءادل ةشرابم رثكلأا ةيبطلا فيلاكتلا ىزعت جاتنتسلاا
 دعاست نأ نكملما نمو .ةيحصلا تايجولونكتلا  لىإ لولأا طمنلا
 يركسلا  لىع ةرطيسلل دراولما  عيزوت مييقت  ةداعإ  في تانايبلا  هذه
 .ليزابرلا في ةيمومعلا ةيحصلا ةياعرلا ماظن في لولأا طمنلا نم
on the health-care system remains un-
determined.
Evaluating the costs associated with 
diabetes becomes increasingly impor-
tant in light of the expected increase 
in the prevalence of the disease and 
its complications. In the present study, 
the costs of type 1 diabetes increased 
in proportion to the duration of the 
diabetes. This increase may have an 
impact on health spending in the future 
because chronic complications become 
more prevalent as diabetes progresses. 
In a Canadian study,21 the impact of 
diabetes was projected over a 16-year 
period. It found a projected increase in 
the number of diabetes patients from 
1.4 to 2.4 million and a projected 75% 
increase in health-care costs. However, 
the expected prevalence of diabetes and 
the costs associated with the disease 
increased in parallel with the ageing of 
the population; the overall health-care 
costs for the youngest members of the 
population are not expected to increase 
substantially. Despite this projection, 
data from the Centers for Disease Con-
trol and Prevention in Atlanta, United 
States, indicate that annual health-care 
costs among youths with diabetes are six 
times higher than among youths without 
diabetes.22
Intervention studies, such as the 
DCCT, have shown that intensive treat-
ment during the early stages of T1DM 
reduces the risk of microvascular and 
macrovascular complications.2 Clinical 
and economic trials can furnish data 
that can guide economic policy deci-
sions aiming to reduce direct costs 
by reallocating resources towards the 
prevention of acute and chronic com-
plications.
To our knowledge, this study is the 
first one in Latin America to estimate 
the costs associated with T1DM using 
data obtained from medical records. It 
is representative of the distribution of 
T1DM in Brazil and included different 
ethnic and socioeconomic groups from 
all parts of the country.
Some limitations must be ad-
dressed. The data used in this study were 
acquired from medical record reviews; 
thus, if any data were missing from the 
records, a data collection bias would 
have led to an underestimation of the 
costs. Also, comparisons with studies 
conducted in other countries are ham-
pered by the use of different currencies. 
Indeed, inflation and exchange rate dif-
ferences may account for some of the 
discrepancies. Furthermore, the real 
costs of hospitalization for hypergly-
caemia or diabetic ketoacidosis exceed 
the amount paid by the NBHCS, which 
probably reimburses little more than 
the costs of medications and laboratory 
tests and excludes daily hospital stay and 
staff labour costs (data not shown). This, 
plus the fact that reimbursement by the 
NBHCS for medical and non-medical 
visits and procedures is low, could have 
led to an underestimation of the direct 
medical costs associated with diabe-
tes from the perspective of the public 
health-care system in Brazil.
In conclusion, T1DM has an im-
portant economic and social impact 
on the health-care system in Brazil. 
The direct costs associated with the 
disease are high, especially those as-
sociated with drug treatment and sup-
plies for insulin administration and 
SMBG. These findings should encour-
age a reassessment of the distribution 
of resources for managing T1DM and 
trigger cost-effectiveness studies to 
optimize the long-term treatment of 
T1DM in Brazil. ■
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摘要




方法 2008 至 2010 年间，在巴西 20 个城市中的
28 个公立诊所执行全国范围内多中心的回顾式横断
面研究。研究纳入 3180 名 I 型糖尿病（平均年龄







结果 人均平均年度直接医疗成本是 1319.15 美元。
治疗相关费用（每年每个病人 1216.33 美元）占总直
接医疗成本的 92.20%。胰岛素用药和 SMBG（每年
每个病人 696.78 美元）占总成本的 52.82%。医疗
流程和血液透析合计占直接医疗成本的 5.73%（每年
每个病人 75.64 美元）。诊疗占直接医疗成本的 1.94%
（每年每个病人 25.62 美元）。




Coût du diabète de type 1: une étude multicentrique à l’échelle nationale réalisée au Brésil
Objectif Déterminer les coûts médicaux directs du diabète gras de 
type 1 (DT1) pour le système de santé national brésilien (SSNB) et quantifier 
la contribution de chaque composante individuelle au coût total.
Méthodes Une étude rétrospective, transversale, multicentrique et à 
l’échelle nationale a été menée entre 2008 et 2010 dans 28 cliniques 
publiques de 20 villes brésiliennes. Cette étude incluait 3180 patients 
atteints de DT1 (moyenne d’âge de 22 ans ± 11,8) qui ont été interrogés 
alors qu’ils étaient pris en charge par le SSNB. En moyenne, ils étaient 
atteints par la maladie depuis 10,3 ans (± 8). Les coûts des tests et des 
interventions médicales, des pompes à insuline et des équipements pour 
son administration, ainsi que des fournitures pour l’autosurveillance du 
taux de glycémie (ASTG) ont été obtenus à partir de sources provenant 
du système de santé national et local sur 2010–2011. Les coûts médicaux 
directs annuels ont été calculés en ajoutant les coûts des médicaments, 
des fournitures, des consultations médicales, des interventions et des 
hospitalisations au cours de l’année précédant l’enquête.
Résultats La moyenne du coût médical direct annuel par habitant 
s’élevait à 1319,15 dollars. Les dépenses liées au traitement – 
1216,33 dollars par patient et par an –ont représenté 92,20% du total 
des coûts médicaux directs. L’équipement nécessaire à l’administration 
d’insuline et à l’ASTG (696,78 dollars par patient et par an) a totalisé 
52,82% du total de ces coûts. Dans l’ensemble, les interventions 
médicales et l’hémodialyse ont représenté 5,73% (75,64 dollars par 
patient et par an) des coûts médicaux directs, et les consultations ont 
représenté 1,94% de ces mêmes coûts (25,62 dollars par patient et 
par an).
Conclusion Les technologies de la santé ont constitué la majeure partie 
des coûts médicaux directs du DT1. Ces données peuvent être utilisées 
pour réévaluer la distribution des ressources pour la prise en charge du 
DT1 par le système de santé publique brésilien.
Резюме
Расходы на лечение сахарного диабета 1-го типа: национальное многоцентровое исследование в 
Бразилии
Цель Определить уровень прямых медицинских расходов, 
связанных с сахарным диабетом 1-го типа (T1DM), в Национальной 
системе здравоохранения Бразилии (NBHCS) и количественно 
определить долю каждого отдельного компонента в общей 
сумме расходов.
Методы В 2008-2010 гг. было проведено ретроспективное, 
перекрестное, национальное многоцентровое исследование 
в 28 государственных клиниках в 20 городах Бразилии. В 
исследовании участвовало 3180 пациентов с T1DM (средний 
возраст: 22 года ± 11,8), опрошенных во время прохождения 
лечения в Национальной системе здравоохранения Бразилии. 
Средняя продолжительность заболевания диабетом у этих 
пациентов составляла 10,3 лет (± 8,0). Данные по стоимости 
тестов и медицинских процедур, дозаторов инсулина и 
расходных материалов, а также материалов, шприцев и игл для 
самостоятельного контроля уровня глюкозы в крови (SMBG) 
были получены из национальных и местных источников системы 
здравоохранения в течение 2010-2011 гг. Ежегодные прямые 
медицинские расходы рассчитывались методом сложения 
стоимости медикаментов, расходных материалов, тестов, 
медицинских консультаций, процедур и госпитализации за год, 
предшествующий опросу.
Результаты Среднегодовые прямые медицинские расходы на 
душу населения составили 1319,15 долларов США. Затраты 
на лечение – 1216,33 долларов США на пациента в год – 
составили 92,20% от общих прямых медицинских расходов. 
На самостоятельный контроль уровня глюкозы в крови и 
расходные материалы для ввода инсулина (696,78 долларов США 
на пациента в год) приходилось 52,82% от этой общей суммы 
расходов. Медицинские процедуры и гемодиализ в совокупности 
составили 5,73% (75,64 долларов США на пациента в год) от 
прямых медицинских расходов. На консультации приходилось 
1,94% прямых медицинских расходов (25,62 долларов США на 
пациента в год).
Вывод Основная доля прямых медицинских расходов на лечение 
T1DM приходилась на медицинские технологии. Эти данные 
могут способствовать пересмотру распределения ресурсов 
для лечения T1DM в государственной системе здравоохранения 
Бразилии.
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Resumen
El coste de la diabetes tipo 1: un estudio multicéntrico a nivel nacional en Brasil
Objetivo Determinar los costes médicos directos de la diabetes mellitus 
de tipo 1 (DMT1) para el sistema nacional brasileño de atención sanitaria 
(NBHCS, según sus siglas en inglés) y cuantificar la contribución de cada 
componente individual al coste total.
Métodos Se llevó a cabo un estudio multicéntrico retrospectivo 
transversal a nivel nacional entre los años 2008 y 2010 en 28 clínicas 
públicas de 20 ciudades brasileñas. El estudio incluyó 3180 pacientes 
con DMT1 (edad media de 22 años ± 11,8), que fueron entrevistados 
mientras recibían atención sanitaria del NBHCS. La duración media 
de su diabetes fue de 10,3 años (± 8,0). Los costes de las pruebas y 
procedimientos médicos, las bombas de insulina y provisiones para 
la administración, así como suministros para la automonitorización 
de la glucosa en sangre (AMG) se obtuvieron de las fuentes de los 
sistemas de salud nacionales y locales para el periodo 2010-2011. Los 
costes médicos directos anuales se obtuvieron sumando los costes de 
los medicamentos, suministros, pruebas, consultas y procedimientos 
médicos y hospitalizaciones durante el año anterior a la entrevista.
Resultados El coste medio directo anual por cápita fue de 1319,15 
dólares americanos (US$). Los gastos relacionados con el tratamiento, 
US$ 1216,33 por paciente y año, representaron el 92,20% del total de 
los costes médicos directos. Los suministros para la administración de 
insulina y la AMG (US$ 696,78 por paciente y año) significaron el 52,82% 
de esos costes totales. En conjunto, los procedimientos médicos y la 
hemodiálisis representaron el 5,73% (US$ 75,64 por paciente y año) de 
los costes médicos directos. Las consultas fueron el 1,94% de los costes 
médicos directos (US$ 25,62 por paciente y año).
Conclusión Las tecnologías sanitarias representaron la mayoría de los 
costes médicos directos de la DMT1. Estos datos pueden servir para 
volver a examinar la distribución de los recursos para la gestión de la 
diabetes de tipo 1 en el sistema de salud pública de Brasil.
References
1. American Diabetes Association. Standards of medical care in 
diabetes–2012. Diabetes Care 2012;35(Suppl 1):S11–63. doi: http://dx.doi.
org/10.2337/dc12-s011 PMID:22187469
2. The Diabetes Control and Complications Trial Research Group. The 
effect of intensivetreatment of diabetes on the development and 
progression of long-term complications in insulin-dependent diabetes 
mellitus. N Engl J Med 1993;329:977–86. doi: http://dx.doi.org/10.1056/
NEJM199309303291401 PMID:8366922
3. DIAMOND Project Group. Incidence and trends of childhood Type 1 
diabetes worldwide 1990–1999. Diabet Med 2006;23:857–66. 
PMID:16911623
4. Ferreira SR, Franco LJ, Vivolo MA, Negrato CA, Simoes AC, Ventureli 
CR. Population-based incidence of IDDM in the state of São Paulo, 
Brazil. Diabetes Care 1993;16:701–4. doi: http://dx.doi.org/10.2337/
diacare.16.5.701 PMID:8495607
5. Negrato CA, Dias JP, Teixeira MF, Dias A, Salgado MH, Lauris JR et al. 
Temporal trends in incidence of Type 1 diabetes between 1986 and 2006 in 
Brazil. J Endocrinol Invest 2010;33:373–7. PMID:19620822
6. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR 
et al. Mortality from heart disease in a cohort of 23,000 patients with 
insulin-treated diabetes. Diabetologia 2003;46:760–5. doi: http://dx.doi.
org/10.1007/s00125-003-1116-6 PMID:12774166
7. Barceló A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin 
America and the Caribbean. Bull World Health Organ 2003;81:19–27. 
PMID:12640472
8. American Diabetes Association. Economic costs of diabetes in the US in 
2007. Diabetes Care 2008;31:596–615. doi: http://dx.doi.org/10.2337/dc08-
9017 PMID:18308683 PMID:18308683
9. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ 
et al.;  Diabetes Control and Complications Trial/Epidemiology of Diabetes 
Interventions and Complications (DCCT/EDIC) Study Research Group. 
Intensive diabetes treatment and cardiovascular disease in patients 
with type 1 diabetes. N Engl J Med 2005;353:2643–53. doi: http://dx.doi.
org/10.1056/NEJMoa052187 PMID:16371630
10. The Diabetes Control and Complications Trial Research Group. Lifetime 
benefits and costs of intensive therapy as practiced in the diabetes control 
and complications trial. JAMA 1996;276:1409–15. doi: http://dx.doi.
org/10.1001/jama.1996.03540170053032 PMID:8892716
11. Gomes MB, Coral M, Cobas RA, Dib SA, Canani LH, Nery M et al. Prevalence 
of adults with type 1 diabetes who meet the goals of care in daily clinical 
practice: a nationwide multicenter study in Brazil. Diabetes Res Clin Pract 
2012;97:63–70. doi: http://dx.doi.org/10.1016/j.diabres.2012.02.008 
PMID:22397904
12. Govan L, Wu O, Briggs A, Colhoun HM, McKnight JA, Morris AD et al.;  
Scottish Diabetes Research Network Epidemiology Group. Inpatient costs 
for people with type 1 and type 2 diabetes in Scotland: a study from the 
Scottish Diabetes Research Network Epidemiology Group. Diabetologia 
2011;54:2000–8. doi: http://dx.doi.org/10.1007/s00125-011-2176-7 
PMID:21607632
13. González JC, Walker JH, Einarson TR. Cost-of-illness study of type 2 diabetes 
mellitus in Colombia. Rev Panam Salud Publica 2009;26:55–63. doi: http://
dx.doi.org/10.1590/S1020-49892009000700009 PMID:19814883
14. Bahia LR, Araújo DV, Schaan BD, Dib SA, Negrato CA, Leão MPS et al. The 
costs of type 2 diabetes mellitus outpatient care in the Brazilian public 
health system. Value Health 2011;14(Suppl 1):S137–40. doi: http://dx.doi.
org/10.1016/j.jval.2011.05.009 PMID:21839888
15. Associação Brasileira de Empresas de Pesquisa [Internet]. Critério de 
classificação econômica Brasil (CCEB) - em vigor a partir de 01/02/2012. São 
Paulo: ABEP; 2013. Portuguese. Available from: http://www.abep.org/novo/
Content.aspx?SectionID=84 [accessed 30 March 2013].
16. Sistema Único de Saúde [Internet]. Portal da saúde, banco de preços em 
saúde. SUS; 2013. Portuguese. Available from: http://portal.saude.gov.br/
portal/saude/Gestor/area.cfm?id_area=939 [accessed 30 March 2013].
17. Shrestha SS, Zhang P, Albright A, Imperatore G. Medical expenditures 
associated with diabetes among privately insured US youth in 2007. 
Diabetes Care 2011;34:1097–101.  doi: http://dx.doi.org/10.2337/dc10-2177 
PMID:21525502
18. Gomes MB, de Mattos Matheus AS, Calliari LE, Luescher JL, Manna TD, 
Savoldelli RD et al. Economic status and clinical care in young type 1 
diabetes patients: a nationwide multicenter study in Brazil. Acta Diabetol 
2012. Epub 12 June. PMID:22688518
19. Instituto Brasileiro de Geografia e Estatística [Internet]. Uma análise das 
condições de vida da população brasileira 2010. Rio de Janeiro: IBGE; 2013. 
Portuguese. Available from: http://www.ibge.gov.br/home/estatistica/
populacao/condicaodevida/indicadoresminimos/sinteseindicsociais2010/
default.shtm [accessed 30 March 2013].
20. Stern Z, Levy R. The direct cost of type 1 diabetes mellitus in Israel. Diabet 
Med 1994;11:528–33. doi: http://dx.doi.org/10.1111/j.1464-5491.1994.
tb02031.x PMID:7955968
21. Ohinmaa A, Jacobs P, Simpson S, Johnson JA. The projection of prevalence 
and costs of diabetes in Canada: 2000 to 2016. Canadian J Diabetes 
2004;28:1–8. 
22. Centers for Disease Control and Prevention [Internet]. Diabetes public 
health resource. Atlanta: CDC; 2012. Available from: http://www.cdc.gov/
diabetes/ [accessed 30 March 2013].
